

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

| SAMPLE ID: | PRODUCT NAME: |
|------------|---------------|
|------------|---------------|

Strength:

Lot Number:

Expiration Date:

| CANNABINOIDS* | MG/UNIT | METHOD |
|---------------|---------|--------|
|---------------|---------|--------|

CBD

CBDA

d9-THC

THCA-A

d8-THC

THCV

CBDV

CBDVA

CBGA

CBG

CBN

CBC

CBL

Total Cannabinoids

Sample Size

THC by Mass

| HEAVY METALS* | STATUS (PASS/FAIL) | METHOD |
|---------------|--------------------|--------|
|---------------|--------------------|--------|

Arsenic

Cadmium

Mercury

Lead

CV Sciences Certificate of Analysis



| MICROBIOLOGY* | STATUS (PASS/FAIL) | METHOD |
|-------------------|--------------------|--------|
| Mold/Mildew/Yeast | | |
| Aerobic Bacteria | | |
| Coliforms | | |
| E. Coli | | |
| Salmonella | | |
| Pseudomonas | | |

| PESTICIDES** | STATUS (PASS/FAIL) | METHOD |
|------------------|--------------------|--------|
| Total Pesticides | | |
| Mycotoxins | Pass | |

| RESIDUAL SOLVENTS** | STATUS (PASS/FAIL) | METHOD |
|-------------------------|--------------------|--------|
| Total Residual Solvents | | |

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.†

†Tested analytes and limits were set by CV Sciences, Inc.



DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

QUALITY APPROVAL

| Prepared By / Date | Approved By / Date | Status |
|--------------------|---|---|
| Vandana Kothari |  <small>Signed by Vandana Kothari</small> |  <small>I Approve this document</small> <small>21-Nov-2024 08:57 PST</small> |

87A410FFF03248738900BEE00868E359



November 14, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 563484
Sample No. 1257716

SAMPLE INFORMATION

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Category (Type) Non-Inhalable Edible (Capsule)
Received November 13, 2024

ANALYTICAL RESULTS


Analysis Cannabinoid Profile (Non-Plant) ✔ Pass
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date November 13, 2024 to November 14, 2024

| Cannabinoid | mg/g | % | mg/serving | mg/package | Labeled mg/serving | % Difference | Status |
|---------------------------|---------|-------|------------|------------|--------------------|--------------|--------|
| Δ8-THC | ND | ND | ND | ND | - | - | - |
| Δ9-THC | <LOQ | <LOQ | <LOQ | <LOQ | - | - | Pass |
| Δ9-THCA | ND | ND | ND | ND | - | - | - |
| THCV | ND | ND | ND | ND | - | - | - |
| THCVA | ND | ND | ND | ND | - | - | - |
| CBD | 39.18 | 3.918 | 16.38 | 982.52 | 15 | 9.17 | - |
| CBDA | ND | ND | ND | ND | - | - | - |
| CBC | ND | ND | ND | ND | - | - | - |
| CBCA | ND | ND | ND | ND | - | - | - |
| CBDV | <LOQ | <LOQ | <LOQ | <LOQ | - | - | - |
| CBG | <LOQ | <LOQ | <LOQ | <LOQ | - | - | - |
| CBGA | ND | ND | ND | ND | - | - | - |
| CBN | ND | ND | ND | ND | - | - | - |
| Total THC | <LOQ | <LOQ | <LOQ | <LOQ | - | - | - |
| Total CBD | 39.18 | 3.918 | 16.38 | 982.52 | - | - | - |
| Total Cannabinoids | 39.18 | 3.918 | 16.38 | 982.52 | - | - | - |
| Sum of Cannabinoids | 39.18 | 3.918 | 16.38 | 982.52 | - | - | - |
| Serving Weight (g) | 0.41792 | | | | | | |
| Package Weight (g) | 25.08 | | | | | | |

Comments

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

Reported by
Anresco, Inc.


Ali Sweeney
Analyst II

November 14, 2024



ND = None Detected
LOD = Limit of Detection (0.1333 mg/g)
LOQ = Limit of Quantitation (0.4000 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

November 15, 2024

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 563484
Sample No. 1257716**SAMPLE INFORMATION**

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Category (Type) Non-Inhalable Edible (Capsule)
Received November 13, 2024

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date November 13, 2024 to November 15, 2024

| Analyte | LOD/LOQ (ppm) | Findings (ppm) | Limit (ppm) | Status |
|---------------------|---------------|----------------|-------------|--------|
| Abamectin | 0.04/0.10 | ND | 0.3 | Pass |
| Acephate | 0.02/0.06 | ND | 5.0 | Pass |
| Acequinocyl | 0.04/0.10 | ND | 4.0 | Pass |
| Acetamiprid | 0.017/0.05 | ND | 5.0 | Pass |
| Aldicarb | 0.02/0.06 | ND | 0.02 | Pass |
| Azoxystrobin | 0.02/0.06 | ND | 40.0 | Pass |
| Bifenazate | 0.02/0.06 | ND | 5.0 | Pass |
| Bifenthrin | 0.04/0.10 | ND | 0.5 | Pass |
| Boscalid | 0.02/0.06 | ND | 10.0 | Pass |
| Captan | 0.2/0.6 | ND | 5.0 | Pass |
| Carbaryl | 0.02/0.06 | ND | 0.5 | Pass |
| Carbofuran | 0.017/0.05 | ND | 0.017 | Pass |
| Chlorantraniliprole | 0.02/0.06 | ND | 40.0 | Pass |
| Chlordane | 0.02/0.06 | ND | 0.02 | Pass |
| Chlorfenapyr | 0.02/0.06 | ND | 0.02 | Pass |
| Chlorpyrifos | 0.02/0.06 | ND | 0.02 | Pass |
| Clofentezine | 0.02/0.06 | ND | 0.5 | Pass |
| Coumaphos | 0.02/0.06 | ND | 0.02 | Pass |
| Cyfluthrin | 0.10/0.30 | ND | 1.0 | Pass |
| Cypermethrin | 0.10/0.30 | ND | 1.0 | Pass |
| Daminozide | 0.017/0.05 | ND | 0.017 | Pass |
| DDVP (Dichlorvos) | 0.013/0.04 | ND | 0.013 | Pass |
| Diazinon | 0.017/0.05 | ND | 0.2 | Pass |
| Dimethoate | 0.017/0.05 | ND | 0.017 | Pass |
| Dimethomorph | 0.017/0.05 | ND | 20.0 | Pass |
| Ethoprop(hos) | 0.02/0.06 | ND | 0.02 | Pass |
| Etofenprox | 0.02/0.06 | ND | 0.02 | Pass |
| Etoxazole | 0.02/0.06 | ND | 1.5 | Pass |
| Fenhexamid | 0.017/0.05 | ND | 10.0 | Pass |
| Fenoxycarb | 0.02/0.06 | ND | 0.02 | Pass |
| Fenpyroximate | 0.02/0.06 | ND | 2.0 | Pass |

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

| Analyte | LOD/LOQ (ppm) | Findings (ppm) | Limit (ppm) | Status |
|-------------------------|---------------|----------------|-------------|--------|
| Fipronil | 0.02/0.06 | ND | 0.02 | Pass |
| Flonicamid | 0.02/0.06 | ND | 2.0 | Pass |
| Fludioxonil | 0.02/0.06 | ND | 30.0 | Pass |
| Hexythiazox | 0.02/0.06 | ND | 2.0 | Pass |
| Imazalil | 0.02/0.06 | ND | 0.02 | Pass |
| Imidacloprid | 0.02/0.06 | ND | 3.0 | Pass |
| Kresoxim Methyl | 0.02/0.06 | ND | 1.0 | Pass |
| Malathion | 0.017/0.05 | ND | 5.0 | Pass |
| Metalaxyl | 0.017/0.05 | ND | 15.0 | Pass |
| Methiocarb | 0.02/0.06 | ND | 0.02 | Pass |
| Methomyl | 0.013/0.04 | ND | 0.1 | Pass |
| Methyl parathion | 0.02/0.06 | ND | 0.02 | Pass |
| Mevinphos | 0.02/0.06 | ND | 0.02 | Pass |
| Myclobutanil | 0.02/0.06 | ND | 9.0 | Pass |
| Naled | 0.017/0.05 | ND | 0.5 | Pass |
| Oxamyl | 0.013/0.04 | ND | 0.2 | Pass |
| Paclobutrazol | 0.02/0.06 | ND | 0.02 | Pass |
| Pentachloronitrobenzene | 0.017/0.05 | ND | 0.2 | Pass |
| Permethrins | 0.10/0.30 | ND | 20.0 | Pass |
| Phosmet | 0.02/0.06 | ND | 0.2 | Pass |
| Piperonyl Butoxide | 0.017/0.05 | ND | 8.0 | Pass |
| Prallethrin | 0.04/0.10 | ND | 0.4 | Pass |
| Propiconazole | 0.02/0.06 | ND | 20.0 | Pass |
| Propoxur | 0.013/0.04 | ND | 0.013 | Pass |
| Pyrethrins | 0.15/0.50 | ND | 1.0 | Pass |
| Pyridaben | 0.017/0.05 | ND | 3.0 | Pass |
| Spinetoram | 0.02/0.06 | ND | 3.0 | Pass |
| Spinosad | 0.02/0.06 | ND | 3.0 | Pass |
| Spiromesifen | 0.04/0.10 | ND | 12.0 | Pass |
| Spirotetramat | 0.02/0.06 | ND | 13.0 | Pass |
| Spiroxamine | 0.017/0.05 | ND | 0.017 | Pass |
| Tebuconazole | 0.02/0.06 | 0.078 | 2.0 | Pass |
| Thiacloprid | 0.013/0.04 | ND | 0.013 | Pass |
| Thiamethoxam | 0.02/0.06 | ND | 4.5 | Pass |
| Trifloxystrobin | 0.02/0.06 | <LOQ (0.036) | 30.0 | Pass |

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation

Amy Lee
Senior Analyst

November 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

November 15, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 563484
Sample No. 1257716

SAMPLE INFORMATION

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Category (Type) Non-Inhalable Edible (Capsule)
Received November 13, 2024

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date November 13, 2024 to November 15, 2024

| Analyte | LOD/LOQ (ppm) | Findings (ppm) | Limit (ppm) | Status |
|--------------------------------------|---------------|----------------|-------------|--------|
| 1,2-Dichloroethane | 0.5/0.5 | ND | 1 | Pass |
| Acetone | 57/200 | ND | 5000 | Pass |
| Acetonitrile | 56/200 | ND | 410 | Pass |
| Benzene | 0.5/0.5 | ND | 1 | Pass |
| n-Butane | 45/200 | ND | 5000 | Pass |
| Chloroform | 0.5/0.5 | ND | 1 | Pass |
| Ethanol | 37/200 | ND | 5000 | Pass |
| Ethyl acetate | 38/200 | ND | 5000 | Pass |
| Ethyl ether | 37/200 | ND | 5000 | Pass |
| Ethylene oxide | 0.1/0.5 | ND | 1 | Pass |
| n-Heptane | 135/200 | ND | 5000 | Pass |
| n-Hexane | 49/200 | ND | 290 | Pass |
| Isopropyl alcohol | 57/200 | ND | 5000 | Pass |
| Methanol | 37/200 | ND | 3000 | Pass |
| Methylene chloride | 0.1/0.5 | ND | 1 | Pass |
| n-Pentane | 37/200 | ND | 5000 | Pass |
| Propane | 72/200 | ND | 5000 | Pass |
| Toluene | 49/200 | ND | 890 | Pass |
| Total xylenes (ortho-, meta-, para-) | 58/200 | ND | 2170 | Pass |
| Trichloroethylene | 0.5/0.5 | ND | 1 | Pass |

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Alma Dorantes
Analyst I



November 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

November 15, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 563484
Sample No. 1257716

SAMPLE INFORMATION

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Category (Type) Non-Inhalable Edible (Capsule)
Received November 13, 2024

ANALYTICAL RESULTS

Analysis Mycotoxins Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date November 13, 2024 to November 15, 2024

| Analyte | LOD/LOQ (ppb) | Findings (ppb) | Limit (ppb) | Status |
|------------------|---------------|----------------|-------------|--------|
| Aflatoxin B1 | 2/5 | ND | - | - |
| Aflatoxin B2 | 2/5 | ND | - | - |
| Aflatoxin G1 | 2/5 | ND | - | - |
| Aflatoxin G2 | 2/5 | ND | - | - |
| Total Aflatoxins | 8/20 | ND | 20 | Pass |
| Ochratoxin A | 6/18 | ND | 20 | Pass |

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation




Amy Lee
Senior Analyst

November 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

November 19, 2024

CV SCIENCES, INC.
 9530 Padgett Street, Suite 107
 San Diego, CA 92126

Order No. 563484
 Sample No. 1257716

SAMPLE INFORMATION

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Received November 13, 2024

ANALYTICAL RESULTS

Analysis Date November 13, 2024 to November 19, 2024

| Findings | Analysis | Results | Method |
|----------|----------------------|---------------|----------------------------|
| | Standard Plate Count | <10 cfu/g | FDA BAM |
| | Yeast | <10 cfu/g | FDA BAM |
| | Mold | <10 cfu/g | FDA BAM |
| | Coliforms | <10 cfu/g | FDA BAM - ECC AGAR |
| | Escherichia coli | <10 cfu/g | FDA BAM - ECC AGAR |
| | Salmonella | Negative /10g | MF-MICRO-11 (AOAC 2016.01) |
| | Staph aureus | Negative /10g | USP <62> |

Reported by
Anresco, Inc.



Allen Zhu
 Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

November 15, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 563484
Sample No. 1257716

SAMPLE INFORMATION

Description FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26
Lot Number A107390924
Category (Type) Non-Inhalable Edible (Capsule)
Received November 13, 2024

ANALYTICAL RESULTS

Analysis Heavy Metals ✔ Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF-CHEM-16
Analysis Date November 13, 2024 to November 15, 2024

| Analyte | LOD/LOQ (µg/g) | Findings (µg/g) | Limit (µg/g) | Status |
|---------|----------------|-----------------|--------------|--------|
| Arsenic | 0.02/0.05 | <LOQ | 1.5 | Pass |
| Cadmium | 0.02/0.05 | ND | 0.5 | Pass |
| Mercury | 0.02/0.05 | ND | 3 | Pass |
| Lead | 0.02/0.125 | ND | 0.5 | Pass |

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Eric Tam
Senior Chemist

November 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".


Certificate Of Completion

| | |
|---|--------------------------------|
| Envelope Id: DA69FB7CFAC74A6A8190FBA9F90929EF | Status: Completed |
| Subject: FP-24-0113 pluscbd 15mg 60ct Softgels SKU 107 exp 02/26 A107390924 | |
| Source Envelope: | |
| Document Pages: 9 | Signatures: 1 |
| Certificate Pages: 1 | Initials: 0 |
| AutoNav: Enabled | Envelope Originator: |
| Envelopeld Stamping: Enabled | Vandana Kothari |
| Time Zone: (UTC-08:00) Pacific Time (US & Canada) | vandana.kothari@cvsciences.com |
| | IP Address: 64.207.219.136 |

Record Tracking

| | | |
|-----------------------|--------------------------------|--------------------|
| Status: Original | Holder: Vandana Kothari | Location: DocuSign |
| 11/21/2024 8:11:37 AM | vandana.kothari@cvsciences.com | |

Signer Events

| Signer Events | Signature | Timestamp |
|---|--|---|
| Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required) |  Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document | Sent: 11/21/2024 8:12:30 AM Viewed: 11/21/2024 8:57:06 AM Signed: 11/21/2024 8:57:46 AM |

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events

| Signature | Timestamp |
|-----------|-----------|
|-----------|-----------|

Editor Delivery Events

| Status | Timestamp |
|--------|-----------|
|--------|-----------|

Agent Delivery Events

| Status | Timestamp |
|--------|-----------|
|--------|-----------|

Intermediary Delivery Events

| Status | Timestamp |
|--------|-----------|
|--------|-----------|

Certified Delivery Events

| Status | Timestamp |
|--------|-----------|
|--------|-----------|

Carbon Copy Events

| Status | Timestamp |
|--------|-----------|
|--------|-----------|

Witness Events

| Signature | Timestamp |
|-----------|-----------|
|-----------|-----------|

Notary Events

| Signature | Timestamp |
|-----------|-----------|
|-----------|-----------|

Envelope Summary Events

| Status | Timestamps |
|---------------------|--|
| Envelope Sent | Hashed/Encrypted 11/21/2024 8:12:30 AM |
| Certified Delivered | Security Checked 11/21/2024 8:57:06 AM |
| Signing Complete | Security Checked 11/21/2024 8:57:46 AM |
| Completed | Security Checked 11/21/2024 8:57:46 AM |

Payment Events

| Status | Timestamps |
|--------|------------|
|--------|------------|